公开(公告)号：US20240182862A1

公开(公告)日：2024-06-06

申请号：US18533804

申请日：2023-12-08

Applicant: AJINOMOTO CO., INC.

Inventor： Kazuma TAKAHASHI ,  Shizuka BABA ,  Atsushi KONISHI

IPC: C12N5/0775 ,  A61K35/28 ,  A61P1/16 ,  C07K14/47

CPC classification number: C12N5/0668 ,  A61K35/28 ,  A61P1/16 ,  C07K14/4718 ,  C12N2500/90 ,  C12N2501/39 ,  C12N2506/08 ,  C12N2506/45 ,  C12N2533/52

Abstract: A medicament for the prophylaxis or treatment of inflammatory diseases or fibrous diseases, may be produced by inducing mesenchymal stem cells by culturing neural crest cells in a medium composition for inducing mesenchymal stem cells from neural crest cells, comprising a basal medium and corticosteroid, the composition having a converted concentration of the corticosteroid in the medium composition of not less than 1.25 μM.

公开(公告)号：US20140080790A1

公开(公告)日：2014-03-20

申请号：US14089040

申请日：2013-11-25

Applicant: AJINOMOTO CO., INC.

Inventor： Atsushi KONISHI ,  Munetaka Tokumasu ,  Tamotsu Suzuki ,  Takahiro Koshiba ,  Koji Ohsumi ,  Osamu Ikehara ,  Yuko Kodama

IPC: C07D307/68 ,  C07D405/06 ,  C07F9/655 ,  C07C53/18

CPC classification number: A61K31/4535 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/4525 ,  C07C53/18 ,  C07D277/20 ,  C07D277/56 ,  C07D307/68 ,  C07D333/38 ,  C07D405/06 ,  C07F9/3808 ,  C07F9/65515

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书中所定义，及其药学上可接受的盐可用作具有丝氨酸蛋白酶抑制作用的高血糖抑制剂和用作糖尿病的预防或治疗药物。

公开(公告)号：US20220073873A1

公开(公告)日：2022-03-10

申请号：US17454692

申请日：2021-11-12

Applicant: AJINOMOTO CO., INC.

Inventor： Shizuka BABA ,  Kazuma TAKAHASHI ,  Atsushi KONISHI

IPC: C12N5/079

Abstract: Neural crest cells or corneal epithelial cells may be purified by expansion culturing in the presence of laminin as a scaffold.

公开(公告)号：US20150011511A1

公开(公告)日：2015-01-08

申请号：US14496363

申请日：2014-09-25

Applicant: AJINOMOTO CO., INC.

Inventor： Atsushi KONISHI ,  Munetaka TOKUMASU ,  Tamotsu SUZUKI ,  Takahiro KOSHIBA ,  Koji OHSUMI ,  OSAMU IKEHARA ,  Yuko KODAMA

IPC: C07D307/68 ,  C07D405/06 ,  C07F9/38 ,  C07C53/18

CPC classification number: A61K31/4535 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/4525 ,  C07C53/18 ,  C07D277/20 ,  C07D277/56 ,  C07D307/68 ,  C07D333/38 ,  C07D405/06 ,  C07F9/3808 ,  C07F9/65515

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书中所定义，及其药学上可接受的盐可用作具有丝氨酸蛋白酶抑制作用的高血糖抑制剂和用作糖尿病的预防或治疗药物。

公开(公告)号：US20220348884A1

公开(公告)日：2022-11-03

申请号：US17863832

申请日：2022-07-13

Applicant: AJINOMOTO CO., INC.

Inventor： Shimpei OGAWA ,  Takuya HIGUCHI ,  Shumpei FUROMITSU ,  Yusuke OHYA ,  Megumi NISHIYAMA ,  Atsushi KONISHI

IPC: C12N5/074

Abstract: A medium with a reduced osmotic pressure containing a basal medium, in which the osmotic pressure is adjusted to 150 to 250 mOsm/kg, is useful for culturing cells.

公开(公告)号：US20150313889A1

公开(公告)日：2015-11-05

申请号：US14799130

申请日：2015-07-14

Applicant: AJINOMOTO CO., INC.

Inventor： Atsushi KONISHI ,  Munetaka TOKUMASU ,  Tamotsu SUZUKI ,  Takahiro KOSHIBA ,  Koji OHSUMI ,  Osamu IKEHARA ,  Yuko KODAMA

IPC: A61K31/4535 ,  A61K31/4525 ,  A61K31/381 ,  A61K31/426 ,  A61K31/341 ,  A61K31/4025

CPC classification number: A61K31/4535 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/4525 ,  C07C53/18 ,  C07D277/20 ,  C07D277/56 ,  C07D307/68 ,  C07D333/38 ,  C07D405/06 ,  C07F9/3808 ,  C07F9/65515

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.